Webinar: Impact of Humira biosimilars on the US market

June 15, 2023 | 3:00 p.m. BST
What impact has the US patent expiry of Humira had on patients and will biosimilars dent Humira’s legendary status?
On January 3rd 2023 a key US patent covering Humira adalimumab, the world’s best-selling drug expired. The first biosimilar competitor launched on day 1 of the expiry (Amjevita) and there are already at least 7 others waiting to enter the US market. Having already seen the impact that adalimumab biosimilars have had on Humira sales since European expiry, this webinar will look at potential implications for both biologics and biosimilars developers in the US market.

Looking at 1st quarter results we will dive into the following questions:
  • What impact is this going to have on the US healthcare system?
  • Will more patients benefit as a result and will biosimilars save the system more money?
  • What can be drawn from the European picture by looking at the erosion on Abbvie?
  • What strategies are biosimilar companies introducing to capture market share?
  • What is Abbvie having to do to protects its position?
  • What can other biologics and biosimilars developers learn from this?
  • How is this affecting clinician prescribing and switching behaviors?

Register below and we'll send the details straight to your inbox.



Mike Ward, Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate

As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights and analysis support pharma, biotech, healthcare and medtech stakeholders gain a deeper understanding of market news and trends. Mike has held editorial and content leadership roles at various publications and organizations across the industry.

Dr. William Soliman
Founder, CEO, Accreditation Council for Medical Affairs (ACMA)

William is the Founder, CEO of the Accreditation Council for Medical Affairs (ACMA). He is considered by many to be a pharma industry futurist and has been featured on Fox News, Forbes, Al Jazeera, Yahoo Business TV, ABC News Radio & the Boston Herald. He has over 15 years of experience in the pharmaceutical industry working with several companies such as Merck, Abbvie, Gilead Sciences, and Eisai among others. Dr. Soliman received his PhD from Columbia University & his Bachelors from New York University.

Hamzah Aideed
Manager, Healthcare Research & Data Analytics, Biosimilars, Clarivate

Hamzah is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.